Fundraising FoxSyncona — 2024 Investments
4 investments dated 2024 · listed companies and verified rows first · show all
Autolus Therapeutics develops engineered T cell therapies targeting cancer and autoimmune diseases using proprietary cell programming technology; the company commercializes AUCATZYL, an FDA-approved CAR-T cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia in adults, and maintains a clinical pipeline evaluating additional indications including pediatric leukemia, lupus nephritis, and multiple sclerosis.
London
Martin Pulé(Senior Vice President, Founder, Chief Scientific Officer)Christopher Williams(Senior Vice President, Chief Business Development Officer)Edgar Braendle(Executive Officer)inChristopher Vann(Executive Officer)inDavid Brochu(Executive Officer)inChristian Itin(Chief Executive Officer and Director)in
Co-investorsNextech Invest
iOnctura is a clinical-stage drug development company developing precision oral small-molecule therapies targeting the tumor-stroma-immune interface, with a pipeline including roginolisib and cambritaxestat in cancers such as uveal melanoma and pancreatic cancer.
BiotechDeep TechHealthtechMedical Devices
Catherine Pickering(Co-Founder & CEO)inLars van der Veen(Co-Founder & CSO)inMichael Lahn(CMO)inElizabeth Holt(CBO)inSteven Sciuto(CFO)inMichelle Tsai(COO)in
Co-investorsInkef3B Future Health FundM VenturesVI PartnersXGEN VentureJohnson & Johnson Innovation – JJDC
Purespring develops genetic therapies targeting podocytes to treat renal diseases through its proprietary GlomThera platform.
BiotechDigital HealthHealthtechMedical Devices
Moin Saleem(Co-founder & Chief Scientific Advisor)in
Co-investorsSofinnova PartnersForbionGilde HealthcareAdvent Life SciencesBritish Patient Capital
Resolution develops a macrophage cell therapy to treat end-stage liver disease, aiming to reduce the need for liver transplantation and improve patient outcomes.
BiotechHealthtechMedical Devices
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.